Buy Ryplazim (plasminogen, human-tvmh)

What is Ryplazim (plasminogen, human-tvmh) for?

Ryplazim human-tvmh) is a medicine containing human plasminogen and is used to increase the blood levels of plasminogen in people with plasminogen deficiency type 1 (hypoplasminogenemia).^[1]

It is available in vial form containing 68.8 mg of plasminogen (human).^[1]

How does Ryplazim (plasminogen, human-tvmh) work?

People with plasminogen deficiency have low levels of plasma plasminogen. Plasminogen is a protein that is found in the blood and is made by the liver. Activated plasminogen, which is called plasmin, is the main enzyme responsible for breaking down blood clots. Plasmin is also involved in wound healing, migration of cells, tissue remodeling, formation of new blood vessels and the formation and development of an embryo. Plasminogen deficiency leads to a buildup of fibrin, which causes the development of lesions that damages normal tissue and organ function.^[2,3]

The active ingredient in Ryplazim, plasminogen, is purified from human plasma. Ryplazim temporarily increases plasminogen levels in the patient’s blood, which can temporarily correct the deficiency in plasminogen and reduce or resolve the lesions.^[2,3]

Where has Ryplazim (plasminogen, human-tvmh) been approved?

Ryplazim (plasminogen, human-tvmh) was approved for the treatment of people with NSCLC by:

• The Food and Drug Administration (FDA), USA on June 4, 2021.^[4]

Ryplazim (plasminogen, human-tvmh) received Orphan Drug designation, which is given to assist and encourage drug development for rare diseases. The application also received Fast Track designation, Priority Review, and a Rare Pediatric Disease Priority Review Voucher.^[4]

Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team.

How is Ryplazim (plasminogen, human-tvmh) taken?

The standard dosage is:^[1]

• 6.6 mg/kg body weight given every 2 to 4 days by an injection into a vein (intravenous)

Ryplazim (plasminogen, human-tvmh) can be given at a healthcare facility, or at home by a nurse, caregiver or by injecting it yourself. If the treating doctor believes the patient is able to self-inject or with the help of others at home, detailed instructions and training on preparation and infusion will be given.^[1]

Complete information about Ryplazim (plasminogen, human-tvmh) dosage calculation, infusion preparation and administration can be found in the official prescribing information listed in our references section.^[1]

Note: Please consult with your treating doctor for personalised dosing.

Are there any known adverse reactions or side effects of Ryplazim (plasminogen, human-tvmh)?

Common adverse reactions

The most common side effects (≥10% of patients) listed in the prescribing information include:^[1]

• belly (abdominal) pain
• bloating
• nausea
• tiredness (fatigue)
• extremity pain
• bleedings (hemorrhage)
• constipation
• dry mouth
• headache
• dizziness
• joint pain (arthralgia)
• back pain

Serious adverse reactions

The serious adverse reactions listed in the prescribing information include:1

• bleeding: bleeding at lesion sites or worsening of active bleeding
• tissue sloughing
• transmission of infectious agents
• hypersensitivity reactions
• neutralizing antibodies
• laboratory abnormalities

Use in a specific population

It is not known what the effects of Ryplazim (plasminogen, human-tvmh) are in pregnant women.^[1]

For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information.^[1]

References

1. Full prescribing information [FDA]: Ryplazim (plasminogen, human-tvmh) [PDF]
Liminal BioSciences, Jun 2021

2. Plasminogen deficiency
Liminal BioSciences, cited Jul 2021

3. Castellino FJ, Ploplis VA. Structure and function of the plasminogen/plasmin system.
Thromb Haemost. 2005;93(4):647-654.

4. FDA Approves First Treatment for Patients with Plasminogen Deficiency, a Rare Genetic Disorder
Liminal BioSciences, Jun 2021